Longaeva Partners’s Biohaven BHVN Stock Holding History

Longaeva Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-64,800	Closed	-$732K	–	209
2025 Q4	$732K	Buy	+64,800	New	+$803K	0.06%	104

Other funds holding BHVN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $173M AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Longaeva Partners's BHVN Position: Q1 2026 in Review

Longaeva Partners sold out of Biohaven (BHVN) in Q1 2026, closing a stake of 64,800 shares — an estimated $732K sold.

Longaeva Partners first reported a position in BHVN in Q4 2025 and held it in 1 quarter. The position peaked at $732K in Q4 2025. 275 funds tracked by Wall St. Rank hold BHVN as of Q1 2026.

Longaeva Partners reported no remaining Biohaven position as of Q1 2026 after selling out during the quarter.
Longaeva Partners sold 64,800 Biohaven shares in Q1 2026, an estimated $732K.
Longaeva Partners first reported a position in Biohaven in Q4 2025 and held it in 1 quarter.
Longaeva Partners's Biohaven position peaked at $732K in Q4 2025.
275 funds tracked by Wall St. Rank held Biohaven as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.